PCRX — Pacira BioSciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1396814 ·
Last close
$25.12
Market Cap
$1.00B
52W High
$27.66
52W Low
$18.80
ADV30
518,630
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 192,399,000 | 148,235,000 | 11,861,000 | 4,653,000 | 1,243,978,000 | 205,875,000 | 572,002,000 |
| Mar 2026 | 177,376,000 | 140,963,000 | 4,625,000 | 2,916,000 | 1,208,534,000 | 144,306,000 | 554,641,000 |
| Dec 2025 | 196,873,000 | 156,574,000 | -10,921,000 | 1,637,000 | 1,264,917,000 | 158,545,000 | 571,806,000 |
| Sep 2025 | 179,516,000 | 145,238,000 | 13,153,000 | 5,432,000 | 1,297,577,000 | 147,589,000 | 570,363,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$187,663,000
Investing CF
$94,147,000
Financing CF
$-376,176,000
CapEx
$-8,148,000
Dividends Paid
—
Buybacks
$-148,334,000
EPS Diluted TTM
$0.35
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-191,753,000
Inventory
$134,575,000
Receivables
$132,420,000
ST Investments
$45,156,000
EBIT TTM
$30,952,000
Pretax Income TTM
$17,648,000
Interest Exp TTM
$13,304,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$746,163,968
EBITDA
$123,966,000
Free Cash Flow
$98,341,248
Enterprise Value
$1,171,983,488
Total Cash
$251,031,008
Total Debt
$412,116,992
Shares Out
39,861,886
Trailing EPS
$0.35
Book Value
$16.87
ROE
2.0%
ROA
1.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 726,411,000 | 19,191,000 | 7,034,000 | 1,264,917,000 | 571,806,000 | 693,111,000 | 151,994,000 |
| Dec 2024 | 700,966,000 | 89,872,000 | -99,560,000 | 1,553,516,000 | 775,168,000 | 778,348,000 | 189,389,000 |
| Dec 2023 | 674,978,000 | 87,675,000 | 41,955,000 | 1,574,386,000 | 704,256,000 | 870,130,000 | 154,649,000 |
| Dec 2022 | 666,823,000 | 60,024,000 | 15,909,000 | 1,681,200,000 | 906,190,000 | 775,010,000 | 145,274,000 |
TTM Snapshot
Revenues TTM
$637,137,000
NetIncome TTM
$46,711,000
OpCashFlow TTM
$0
Assets (Latest)
$1,553,516,000
Forward EPS
$3.44
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $25.00 · spot: $25.39 · call volume: 22 · put volume: 22
Expected Move to 2027-01-15:
±$8.55
(33.67%) —
implied range
$16.84 –
$33.94
· ATM straddle on $25.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JANX | Janux Therapeutics, Inc. | $996.53M | $16.30 | — |
| MLTX | MoonLake Immunotherapeutics | $1.02B | $12.04 | — |
| CRVS | Corvus Pharmaceuticals, Inc. | $977.49M | $11.62 | — |
| SVRA | Savara Inc | $1.03B | $5.00 | — |
| ANRO | Alto Neuroscience, Inc. | $1.04B | $26.49 | — |
News headlines (Yahoo Finance, 1h cache)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-09 12:00 · Yahoo
Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?
2026-09-03 15:30 · Yahoo
Pacira (PCRX) Q2 2026 Earnings Call Transcript
2026-08-12 14:42 · Yahoo
Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy?
2026-08-10 06:10 · Yahoo
Pacira BioSciences (PCRX) Could Be 35% Undervalued On Phase 1 Gene Therapy Progress
2026-08-06 21:14 · Yahoo
Pacira BioSciences Q2 Earnings Call Highlights
2026-08-05 02:03 · Yahoo
Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates
2026-08-04 21:40 · Yahoo
Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?
2026-09-04 15:30 · Yahoo
PharmaCorp Rx Inc. Announces Board and Committee Changes
2026-08-27 11:30 · Yahoo
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
2026-08-06 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.